Brief: Voyager Therapeutics Q3 Collaboration Revenue USD 13.365 Million
10/11/2025 13:01
Nov 10 (Reuters) - Voyager Therapeutics Q3 operating income USD -30.594 million. Q3 pretax profit USD -27.809 million Q3 net income USD -27.892 million Q3 basic EPS USD -0.47
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview